Clients need a strategic partner who provides true value and ongoing support

 

Boland’s client partnerships are at the heart of everything they do. But what does that partnership look like from the client’s end? To determine precisely how clients feel about working with Boland and what makes this relationship so unique, Tyler Kern brought in two leaders from one of Boland’s partners, Tatitlek Technologies.

Brian Stokes, Program Manager at Tatitlek Technologies, and Nicole Grant, Operations Control Analyst at Tatitlek Technologies, joined Stefanie Timpke, an Account Executive with Boland, to get down to the bottom of all the secrets that make up this trusted and valued partnership.

“The partnership with Boland transcends Tatitlek Technologies,” Stokes said. “I’ve had a partnership with Boland since 2004. Boland has been instrumental in systemically meeting the goals and objectives of all our contracts at mission-critical facilities. We’re talking about a long-term partnership. It has been, by far, one of the most essential organizations to our success.”

While moved by Stoke’s words, Timpke said that partnerships like the one Boland has with Tatitlek are core to their business.

“What I try to do as the account executive is think like Brian and Nicole,” Timpke said. “I want to mitigate frustration for them. I want to side-step traps before it gets to them for them and be their easy button.”

A critical component that can lead to frustration is downtime due to an HVAC failure in a building where maintaining operations are genuinely necessary. In cases such as this, who a business trusts to maintain their facility is of the utmost importance.

“Several of our buildings are 24-hour monitor,” Grant said. “The services Boland provides aren’t just on-site, but off-site, remotely. They monitor a vast majority of the HVAC equipment. To stay on top of it and to have a timely response for our client, we do heavily depend on Boland to act, respond and turn things around quickly when it comes to any issues we might experience.”

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More
vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More